BACKGROUND: Enhancer of zeste 2 (EZH2), a key component of polycomb repressive complex 2 (PRC2), was of great importance in human cancer pathogenesis. Various studies examined the relationship between EZH2 overexpression with the clinical outcome in patients with digestive cancers, but yielded inconsistent results. METHODS: Electronic databases updated to January 2015 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with digestive cancers. Survival data were aggregated and quantitatively analyzed. RESULTS: We performed a meta-analysis of 10 studies (n = 1,461 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with digestive cancers. Combined hazard ratios suggested that EZH2 overexpression was associated with poor prognosis of overall survival (HR = 1.54, 95% CI: 1.27-1.81) in patients with esophageal cancer. In the stratified analysis, no significantly risks were found among gastric cancer (HR = 0.66, 95% CI: 0.16-1.15) and colorectal cancer (HR = 0.91, 0.63-1.19), indicating EZH2 was not an indicator of poor prognosis in gastric cancer or colorectal cancer. CONCLUSIONS: EZH2 overexpression indicates a poor prognosis for patients with esophageal cancer, but not among gastric cancer or colorectal cancer.
BACKGROUND: Enhancer of zeste 2 (EZH2), a key component of polycomb repressive complex 2 (PRC2), was of great importance in humancancer pathogenesis. Various studies examined the relationship between EZH2 overexpression with the clinical outcome in patients with digestive cancers, but yielded inconsistent results. METHODS: Electronic databases updated to January 2015 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with digestive cancers. Survival data were aggregated and quantitatively analyzed. RESULTS: We performed a meta-analysis of 10 studies (n = 1,461 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with digestive cancers. Combined hazard ratios suggested that EZH2 overexpression was associated with poor prognosis of overall survival (HR = 1.54, 95% CI: 1.27-1.81) in patients with esophageal cancer. In the stratified analysis, no significantly risks were found among gastric cancer (HR = 0.66, 95% CI: 0.16-1.15) and colorectal cancer (HR = 0.91, 0.63-1.19), indicating EZH2 was not an indicator of poor prognosis in gastric cancer or colorectal cancer. CONCLUSIONS:EZH2 overexpression indicates a poor prognosis for patients with esophageal cancer, but not among gastric cancer or colorectal cancer.
Authors: Lauren Krill; Wei Deng; Ramez Eskander; David Mutch; Susan Zweizig; Bang Hoang; Olga Ioffe; Leslie Randall; Heather Lankes; David S Miller; Michael Birrer Journal: Gynecol Oncol Date: 2019-12-13 Impact factor: 5.482